Intercept's Cirrhosis Endpoint Gets FDA Panel Nod For Accelerated Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
But advisory committee members echo FDA concerns about sponsor's ability to complete placebo-controlled confirmatory trial for the obeticholic acid product and weigh changes in enrollment criteria for ongoing study.